Scientists scan bodies to see where new obesity drug goes
NCT ID NCT05202353
Summary
This early-stage study aims to understand how a new weight-loss drug candidate, BI 456906, affects specific targets in the liver and pancreas compared to an approved drug, semaglutide. It will enroll 30 adults with obesity and use special medical scans to see how much of these drugs bind to their targets in the body. The main goal is to gather information on how the drugs work, not to directly measure weight loss in participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Amsterdam UMC, location VUMC
RECRUITINGAmsterdam, 1105 AZ, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.